⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113293 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL5645807 | 0.98 | KDM4E (0.56) | — | |
| Hydrochloric Acid SCHEMBL5649941 | 0.98 | KDM4E (0.56) | — | |
| Formaldehyde SCHEMBL28810279 | 0.94 | KDM4E (0.53) | — | |
| SCHEMBL16835945 | 0.85 | MKNK1 (0.51) | — | |
| SCHEMBL2230245 | 0.85 | — | — | |
| SCHEMBL29896316 | 0.85 | — | — | |
| SCHEMBL7210973 | 0.84 | KDM4E (0.45) | — | |
| Acrylonitrile SCHEMBL28403157 | 0.84 | KDM4E (0.45) | — | |
| SCHEMBL30578438 | 0.83 | MKNK1 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673447-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4536350-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | Nodthera Limited (GB) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | LIEBER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2025034745-A1 | 4-AMINOPIPERIDINES AS SELECTIVE MODULATORS OF POTASSIUM CHANNELS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025026795-A1 | STABILIZED RUBBER COMPOSITION PROVIDING PROTECTION AGAINST OZONE | BASF SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024180018-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023240134-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2023-12-14 | — | — | WO | disclosed |
| EP-4143197-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4142732-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143178-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | disclosed |
| US-20220259215-A1 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | MEDICILON PRECLINICAL RESEARCH (SHANGHAI) LLC. (CN) | 2022-08-18 | — | — | US | disclosed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| WO-2022098992-A1 | USE OF MACROCYCLIC COMPOUNDS IN METHODS OF TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |